Drugs / Erdosteine
Erdosteine
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02332044 | Apr → Sep 2014 | — | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00338507 | Mar 2006 → ? | chronic bronchitis | Adams Respiratory Therapeutics | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT01032304 | Aug 2009 → Mar 2014 | chronic obstructive pulmonary disease | Edmond Pharma | Unknown | Met primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT01176318 | Aug 2010 → Oct 2011 | chronic obstructive pulmonary disease | Hull University Teaching Hospitals NHS Trust | Withdrawn | No outcome recorded Stop: Business |
| Phase not applicable1 trial | ||||||
| — | NCT07329946 | Sep 2026 → Feb 2027 expected | chronic obstructive pulmonary disease | Pierachille Santus, MD, PhD | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT07242222 Comparator | Nov 2025 → Nov 2026 expected | fatty liver disease | Tanta University | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Erdosteine | “Erdosteine 300mg” NCT02332044 ↗ |
| Known as | Erdosteina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1697744 ↗ |
| Known as | Mucotec | ChEMBL registry synonym — accepted as the source's own label CHEMBL1697744 ↗ |
| Known as | RV-144 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1697744 ↗ |
| Modality | Small molecule | — CHEMBL1697744 ↗ |
| Route | Oral | “One 300 mg capsule twice a day” NCT01032304 ↗ |